Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial
Abstract Background Given the persistently large public health impact of neovascular age-related macular degeneration (nARMD) despite many years of anti-VEGF therapy as the first-line treatment and the demonstrated ability of b-blockers to reduce neovascularization, a synergistic effect between an a...
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
BMC
2023-04-01
|
| Edice: | International Journal of Retina and Vitreous |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s40942-023-00460-1 |